Pipelines

Excellamol’s clinical programs are currently in development to provide injectable long-acting OncoPDCs for the treatment of hard-to-reach cancers; diffuse intrinsic pontine glioma (DIPG), glioblastoma (GBM), and pancreatic ductal adenocarcinoma (PDAC). Please find below the candidate drugs and clinical schedule.